Company: CDT
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001641172-25-023191
Chunk: 5

Company: CDT Equity Inc.
Filing Date: 2025-08-12
Form: 424B3
Chunk 5
---
. As the clinical assets have undergone initial pre-clinical and clinical testing conducted by AstraZeneca, we are able to use the safety data generated in these clinical trials to assess which clinical assets to further develop and for which indications.

Through this relationship,
there are considerable active pharmaceutical ingredients (“APIs”)
that were manufactured by AstraZeneca (prior to conducting its clinical trials) and made
available to us. As a result, we may not have to develop the APIs, which is often a time consuming and expensive process, and the APIs already produced were subject to rigorous quality control measures.

In collaboration with SARBORG Limited (“Sarborg”), we intend to leverage an advanced artificial intelligence (AI) and cybernetics platform to evaluate key deliverables across multiple areas of the Company’s operations, including drug repurposing, drug discovery, solid-form identification, and clinical trial monitoring.

The agreements with Sarborg are designed to address longstanding challenges in the pharmaceutical sector, in particular by reducing human error in critical decision-making processes in both clinical development and asset identification. By integrating Sarborg’s algorithmic AI/cybernetics technology, the Company aims to enhance efficiency, lower costs, and accelerate timelines by minimizing human intervention, ultimately optimizing the drug development cycle and giving the Company a competitive
advantage in the sector.

Through this relationship, we will gain access to cutting-edge predictive models and dashboards, enabling the Company to evaluate drug candidates, streamline clinical trials, and optimize asset management with real-time data. These tools will drive faster, more accurate decisions, improving efficiency and reducing costs. We believe, by leveraging these insights, the Company can
differentiate itself in a competitive sector and gain unique data-driven insights that position it
for success across both its current and future asset portfolio.

In addition, we
will retain a perpetual, non-exclusive, royalty-free, and assignable right to use any platform or technology developed by Sarborg in association with the deliverables. Ongoing support from Sarborg will ensure these systems evolve with our
needs, driving long-term innovation in areas like IP creation, regulatory strategy, and clinical trial monitoring. This partnership reinforces our commitment to leveraging AI-driven solutions to accelerate growth, deliver value to stockholders, and maintain a competitive edge in the pharmaceutical sector.

Sarborg is considered to be a related party, as Dr. Andrew Regan, a stockholder, Chief Executive Officer of CDT Equity Inc. and member of CDT Equity Inc.’s Board of Directors (the “Board”),also